Response details at 3 and 6 months: skin, lung, Zubrod PS
UPN . | Total skin score at diagnosis . | BSA* involved at diagnosis, % . | Total skin score at 3 mo . | BSA* involved at 3 mo, % . | Total skin score a 6 mo . | BSA* involved at 6 mo, % . | LFS . | Zubrod . | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
At diagnosis . | At 3 mo . | At 6 mo . | At diagnosis . | At 3 mo . | At 6 mo . | |||||||
1 | 49 | 100 | 46 | 90 | 21 | 40 | 1 | 1 | 0 | |||
1064 | 20 | 40 | 15 | 32 | 5 | 16 | 2 | 2 | 2 | 2 | 2 | 1 |
99991 | 44 | 100 | 20 | 50 | 0 | 0 | 2 | 1 | 0 | |||
99992 | 48 | 100 | 46 | 80 | 0 | 0 | 2 | 2 | 0 | 2 | 2 | 0 |
1467 | 51 | 90 Fasciitis: 90 | 25 | 40 | 0 | 0 | 3 | 1 | 0 | |||
1602 | 18 | 25 | 9 | 10 | 4 | 4 | 2 | 1 | 0 | 1 | 0 | 0 |
434 | 31 | 50 | 15 | 24 | 7 | 10 | 3 | 2 | 1 | 2 | 1 | 1 |
1346 | NE | NE | NE | NE | NE | NE | 6 | 6 | 6 | 4 | 4 | 3 |
122 | 46 | 100 | 22 | 50 | 10 | 20 | 5 | 4 | 4 | 2 | 1 | 0 |
143 | 21 | 25 | 10 | 10 | 4 | 4 | 1 | 0 | 0 | |||
1027 | 43 | 75 | 21 | 30 | 10 | 14 | 2 | 1 | 0 | |||
310AR | 46 | 100 | 18 | 50 | 0 | 0 | 3 | 2 | 0 | 2 | 0 | 0 |
1992MP | 47 | 100 | 0 | 0 | 0 | 0 | 3 | 1 | 0 | 2 | 0 | 0 |
401PP | 51 | 100 | 33 | 50 | 16 | 40 | 3 | 2 | 0 | 3 | 2 | 1 |
8881047 | 42 | 80 | 14 | 30 | 0 | 0 | 2 | 0 | 0 | |||
1023015 | 41 | 75 | 18 | 36 | 0 | 0 | 1 | 1 | 0 | |||
1025779 | 24 | 30 | 24 | 30 | 20 | 20 | 2 | 2 | 2 | 2 | 2 | 2 |
1024411 | 43 | 90 | 40 | 90 | 36 | 90 | 3 | 3 | 2 | |||
9999450 | 23 | 30 | 11 | 12 | 5 | 6 | 1 | 1 | 1 | 3 | 2 | 1 |
Total 19 pt | Range, 18-51 | Mean/range, 73/25-100 | Range, 0-46 | Mean/range, 40/0-90 | Range, 0-36 | Mean/range, 15/0-90 | Range, 1-6 | Range, 1-6 | Range, 0-6 | Range, 1-4 | Range, 0-4 | Range, 0-2 |
UPN . | Total skin score at diagnosis . | BSA* involved at diagnosis, % . | Total skin score at 3 mo . | BSA* involved at 3 mo, % . | Total skin score a 6 mo . | BSA* involved at 6 mo, % . | LFS . | Zubrod . | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
At diagnosis . | At 3 mo . | At 6 mo . | At diagnosis . | At 3 mo . | At 6 mo . | |||||||
1 | 49 | 100 | 46 | 90 | 21 | 40 | 1 | 1 | 0 | |||
1064 | 20 | 40 | 15 | 32 | 5 | 16 | 2 | 2 | 2 | 2 | 2 | 1 |
99991 | 44 | 100 | 20 | 50 | 0 | 0 | 2 | 1 | 0 | |||
99992 | 48 | 100 | 46 | 80 | 0 | 0 | 2 | 2 | 0 | 2 | 2 | 0 |
1467 | 51 | 90 Fasciitis: 90 | 25 | 40 | 0 | 0 | 3 | 1 | 0 | |||
1602 | 18 | 25 | 9 | 10 | 4 | 4 | 2 | 1 | 0 | 1 | 0 | 0 |
434 | 31 | 50 | 15 | 24 | 7 | 10 | 3 | 2 | 1 | 2 | 1 | 1 |
1346 | NE | NE | NE | NE | NE | NE | 6 | 6 | 6 | 4 | 4 | 3 |
122 | 46 | 100 | 22 | 50 | 10 | 20 | 5 | 4 | 4 | 2 | 1 | 0 |
143 | 21 | 25 | 10 | 10 | 4 | 4 | 1 | 0 | 0 | |||
1027 | 43 | 75 | 21 | 30 | 10 | 14 | 2 | 1 | 0 | |||
310AR | 46 | 100 | 18 | 50 | 0 | 0 | 3 | 2 | 0 | 2 | 0 | 0 |
1992MP | 47 | 100 | 0 | 0 | 0 | 0 | 3 | 1 | 0 | 2 | 0 | 0 |
401PP | 51 | 100 | 33 | 50 | 16 | 40 | 3 | 2 | 0 | 3 | 2 | 1 |
8881047 | 42 | 80 | 14 | 30 | 0 | 0 | 2 | 0 | 0 | |||
1023015 | 41 | 75 | 18 | 36 | 0 | 0 | 1 | 1 | 0 | |||
1025779 | 24 | 30 | 24 | 30 | 20 | 20 | 2 | 2 | 2 | 2 | 2 | 2 |
1024411 | 43 | 90 | 40 | 90 | 36 | 90 | 3 | 3 | 2 | |||
9999450 | 23 | 30 | 11 | 12 | 5 | 6 | 1 | 1 | 1 | 3 | 2 | 1 |
Total 19 pt | Range, 18-51 | Mean/range, 73/25-100 | Range, 0-46 | Mean/range, 40/0-90 | Range, 0-36 | Mean/range, 15/0-90 | Range, 1-6 | Range, 1-6 | Range, 0-6 | Range, 1-4 | Range, 0-4 | Range, 0-2 |
CR indicates complete remission; PR, partial remission; MxR, mixed response; NR, no response; LFS-SCORE, Lung Function Score according to NIH consensus conference21 ; and NE, not evaluable.
BSA, body surface area (generalized scleroderma: 75%-100%).